Empowering Discovery,
Enhancing Knowledge
Latest News
Collagen-Targeted MRI Contrast Agent Improves Detection of Small Lung Tumors and Metastases
UAB O’Neal Cancer Center research advances precision imaging through multi-color MRI technology
New MRI approach detects tiny lung tumors and metastases in preclinical study
New MRI Agent Detects Lung Cancer, Hidden Metastases Earlier Than Current Scans
InLighta Patents
InLighta® BioSciences L.L.C. currently has exclusive operational agreement with Georgia State University for a robust patent portfolio related to targeted and non-targeted protein-based contrast agents in the U.S. and international markets.
Key Patents Issued Include:
Contrast Agents and Methods for Preparing Contrast Agents: CA2614486, CN101222878, EP1901659, US8173105, US8367040.
Targeted Contrast Agents and Methods for Targeting Contrast Agents: CA2621763, EP1928507, US9339559, US10525150.
Contrast Agents Methods for Preparing Contrast Agents, and Methods of Imaging: EP2257316, US9956304, US10849993.
Targeted Protein Contrast Agents, Methods of Making and Uses Thereof: US10814020, US11419954, US11426471, US12491268.
Academic Papers and Presentations by Dr. Jenny Yang
Explore Dr. Jenny Yang’s related academic papers, conference presentations, and more.